Why Eli Lilly Stock Is Crushing It Today
Shares of the biopharmaceutical giant Eli Lilly (NYSE: LLY) jumped by as much as 20% in pre-market trading Monday morning. The drugmaker's shares are shooting higher in response to a positive clinical update for its experimental Alzheimer's disease drug known as donanemab.
Donanemab is an experimental antibody designed to target a modified form of beta amyloid. In a midstage trial, the drug reportedly produced a statistically significant slowing in the decline in both cognition and daily function in patients with early symptomatic Alzheimer's disease, when compared to individuals receiving a placebo.
Image source: Getty Images.
Source Fool.com